Gilead Sciences, Inc. (GILD) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Core Insights - Gilead has reported an impressive second quarter with strong performance across all business units, leading to an increase in guidance for both revenue and profit for the year [2][3] - The company has experienced significant growth in its HIV prevention business and has launched a new therapy, Yeztugo, which is considered transformational for HIV prevention [2] Company Performance - Gilead has had a strong year, building on several previous successful years, indicating a positive trajectory for the company [3] - The overall performance reflects the company's strategic focus and operational effectiveness in the biopharma sector [2][3]